Premium
Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma
Author(s) -
Van de Wyngaert Zoé,
Coppo Paul,
Cervera Pascale,
Fabiani Bettina,
Lemonnier MariePaule,
Corre Elise,
Marjanovic Zora,
Aoudjhane Malek,
Mohty Mohamad,
Duléry Rémy
Publication year - 2021
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13568
Subject(s) - brentuximab vedotin , ifosfamide , medicine , carboplatin , etoposide , anaplastic large cell lymphoma , oncology , peripheral t cell lymphoma , refractory (planetary science) , regimen , lymphoma , gastroenterology , chemotherapy , cd30 , t cell , immunology , cisplatin , biology , immune system , astrobiology
Objectives Relapsed/refractory peripheral T‐cell lymphomas (PTCL) have a poor prognosis. We aimed at assessing efficacy of ifosfamide, carboplatin, etoposide (ICE) regimen, a known therapeutic option, to which we added brentuximab‐vedotin (BV). Methods In this study, we retrospectively analyzed patients with PTCL treated with BV‐ICE in our center between July 2014 and March 2018. Results Fourteen patients received BV‐ICE. Median age was 62 years (range, 31‐73). Main histological subtypes were PTCL‐not otherwise specified (29%), angioimmunoblastic T‐cell lymphoma (21%), follicular‐T helper (21%), or anaplastic large‐cell (15%) lymphomas, all were CD30 positive. Overall response was seen in four (29%) patients, and complete response (CR) in two (14%). Most frequent adverse events were infections, and cytopenia. 2‐year progression‐free and overall survival were 14% and 17.5%, respectively. Conclusion Patients with relapsed/refractory PTCL treated with BV‐ICE can achieve CR, but few had a sustained response. This association should preferably be used as a bridge to stem cell transplant or be followed by maintenance therapy.